Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86

Amphastar Pharmaceuticals, Inc.

2024-FY EPS reported $3.06 revenue$731,967,000

Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).
FY 2024 net revenue $732.0M, up 13.6% YoY; GAAP net income $159.5M ($3.06 per share).
Adjusted non-GAAP net income Q4 $47.2M ($0.92 per share); FY $200.8M ($3.86 per share).
Primatene MIST exceeded $100M annual sales in 2024; BAQSIMI factory sales grew 12% vs Q4 2023.
CEO cites progress on proprietary pipeline for 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.